Barclays raised the firm’s price target on Vertex Pharmaceuticals to $446 from $415 and keeps an Overweight rating on the shares. The firm updated its model to include a valuation for VX-548 in neuropathic pain following the Phase 2 data and key opinion leader feedback on painful diabetic peripheral neuropathy. The analyst sees a large market opportunity in both neuropathic pain and acute pain and continues to expect a good chance of positive Phase 3 in acute pain in Q1.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised by $32 at RBC Capital, here’s why
- Vertex Pharmaceuticals price target raised by $75 at Wells Fargo, here’s why
- Vertex Stock (NASDAQ:VRTX) Hit a New 52-Week High Yesterday; Here’s Why
- Early notable gainers among liquid option names on December 13th
- Editas Medicine, Vertex Pharmaceuticals enter license agreement for Cas9
